CA2454627A1 - Methods for improved treatment of cancer with irinotecan based on mrp1 - Google Patents

Methods for improved treatment of cancer with irinotecan based on mrp1 Download PDF

Info

Publication number
CA2454627A1
CA2454627A1 CA002454627A CA2454627A CA2454627A1 CA 2454627 A1 CA2454627 A1 CA 2454627A1 CA 002454627 A CA002454627 A CA 002454627A CA 2454627 A CA2454627 A CA 2454627A CA 2454627 A1 CA2454627 A1 CA 2454627A1
Authority
CA
Canada
Prior art keywords
accession
mrp1
position corresponding
mrp1 gene
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002454627A
Other languages
English (en)
French (fr)
Inventor
Guenther Heinrich
Reinhold Kerb
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epidauros Biotechnologie AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2454627A1 publication Critical patent/CA2454627A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002454627A 2001-07-23 2002-07-23 Methods for improved treatment of cancer with irinotecan based on mrp1 Abandoned CA2454627A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP01117608 2001-07-23
EP01117608.8 2001-07-23
EP02011710 2002-05-24
EP02011710.7 2002-05-24
PCT/EP2002/008200 WO2003013533A2 (en) 2001-07-23 2002-07-23 Methods for improved treatment of cancer with irinotecan based on mrp1

Publications (1)

Publication Number Publication Date
CA2454627A1 true CA2454627A1 (en) 2003-02-20

Family

ID=26076655

Family Applications (5)

Application Number Title Priority Date Filing Date
CA002454627A Abandoned CA2454627A1 (en) 2001-07-23 2002-07-23 Methods for improved treatment of cancer with irinotecan based on mrp1
CA002454640A Abandoned CA2454640A1 (en) 2001-07-23 2002-07-23 Methods for treatment of cancer using irinotecan based on ugt1a1
CA002454637A Abandoned CA2454637A1 (en) 2001-07-23 2002-07-23 Use of irinotecan for improved treatment of cancer based on mdr1
CA002454643A Abandoned CA2454643A1 (en) 2001-07-23 2002-07-23 Methods for the treatment of cancer with irinotecan based on cyp3a5
CA002454648A Abandoned CA2454648A1 (en) 2001-07-23 2002-07-23 Irinotecan for treatment of cancer

Family Applications After (4)

Application Number Title Priority Date Filing Date
CA002454640A Abandoned CA2454640A1 (en) 2001-07-23 2002-07-23 Methods for treatment of cancer using irinotecan based on ugt1a1
CA002454637A Abandoned CA2454637A1 (en) 2001-07-23 2002-07-23 Use of irinotecan for improved treatment of cancer based on mdr1
CA002454643A Abandoned CA2454643A1 (en) 2001-07-23 2002-07-23 Methods for the treatment of cancer with irinotecan based on cyp3a5
CA002454648A Abandoned CA2454648A1 (en) 2001-07-23 2002-07-23 Irinotecan for treatment of cancer

Country Status (6)

Country Link
US (1) US20050032724A1 (https=)
EP (5) EP1408973A2 (https=)
JP (5) JP2005501840A (https=)
AU (5) AU2002328945A1 (https=)
CA (5) CA2454627A1 (https=)
WO (5) WO2003013537A2 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4096037B2 (ja) * 2002-08-12 2008-06-04 国立大学法人滋賀医科大学 グルクロン酸転移酵素遺伝子の変異解析による薬剤代謝活性の予測方法
US6916627B2 (en) 2002-11-27 2005-07-12 St. Jude Children's Research Hospital ATM kinase compositions and methods
US7108992B2 (en) 2002-11-27 2006-09-19 St. Jude Children's Research Hospital ATM kinase compositions and methods
ES2308208T3 (es) 2003-05-30 2008-12-01 University Of Chicago Metodos y composiciones para predecir la toxicidad del irinotecano.
WO2005028645A1 (ja) * 2003-09-24 2005-03-31 Kyushu Tlo Company, Limited ＭＤＲ１遺伝子の５’制御領域におけるＳＮＰｓ
BRPI0415079A (pt) * 2003-10-06 2006-12-12 Novartis Ag biomarcadores para prognóstico de diarréia induzida por droga
JP2005245362A (ja) * 2004-03-05 2005-09-15 Kyowa Medex Co Ltd 肺癌および頭頸部癌の発症危険率を予測する方法
US20070207149A1 (en) * 2004-04-27 2007-09-06 Wellstat Biologics Corporation Cancer treatment using viruses and camptothecins
ES2429041T3 (es) * 2004-06-18 2013-11-12 Genentech, Inc. Combinación de un agente quimioterapéutico y un antagonista de un producto génico para tratar tumores
WO2006076288A2 (en) * 2005-01-11 2006-07-20 Five Prime Therapeutics, Inc. Dna constructs for long-term expression of intravascularly injected naked dna
JP2007060967A (ja) * 2005-08-30 2007-03-15 Tokyo Institute Of Technology 遺伝子多型の検出方法および薬物のスクリーニング方法
US20090325156A1 (en) * 2005-11-10 2009-12-31 Government of the United States of America, as Represented by Secretary, Dept. of Human Services Materials and methods for abcb1 polymorphic variant screening, diagnosis, and treatment
KR101107911B1 (ko) * 2006-11-30 2012-01-25 아크레이 가부시키가이샤 Ｕｇｔ1ａ1 유전자 증폭용 프라이머 셋트, 그것을 포함하는ｕｇｔ1ａ1 유전자 증폭용 시약 및 그 용도
WO2010099508A1 (en) * 2009-02-26 2010-09-02 Theraquest Biosciences, Inc. Extended release oral pharmaceutical compositions of 3-hydroxy-n-methylmorphinan and method of use
WO2011031974A1 (en) * 2009-09-10 2011-03-17 Southern Research Institute Acridine analogs in the treatment of gliomas
EP2542155B1 (en) 2010-03-01 2015-11-04 TAU Therapeutics LLC Method for imaging a disease
JP2011250726A (ja) * 2010-06-01 2011-12-15 Toyo Kohan Co Ltd イリノテカンの副作用の発生危険度を判定する方法及びそのためのキット
JP5945270B2 (ja) 2010-07-20 2016-07-05 バヴァリアン・ノルディック・アクティーゼルスカブ 発現産物を採取するための方法
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
KR102271848B1 (ko) * 2013-11-01 2021-07-01 피트니 파마슈티컬스 피티와이 리미티드 암 치료용 약학적 배합물
CA2962476C (en) * 2014-09-26 2023-09-26 Hi-Stem Ggmbh Novel methods for sub-typing and treating cancer
JP2016088919A (ja) * 2014-11-11 2016-05-23 国立研究開発法人産業技術総合研究所 イベルメクチン又はミルベマイシンｄを有効成分として含む抗癌剤
CN107208163B (zh) * 2015-02-17 2021-01-08 国立大学法人山口大学 辅助对伊立替康副作用的发生风险的预测的方法
US11318131B2 (en) 2015-05-18 2022-05-03 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
JP7042739B2 (ja) 2015-08-20 2022-03-28 イプセン バイオファーム リミティド 癌処置のためのリポソーム型イリノテカン及びｐａｒｐ阻害薬を使用する併用療法
TW202400181A (zh) 2015-08-21 2024-01-01 英商益普生生物製藥有限公司 使用包含微脂伊立替康(irinotecan)及奧沙利鉑(oxaliplatin)之組合療法治療轉移性胰臟癌的方法
CN110402163A (zh) 2016-11-02 2019-11-01 易普森生物制药有限公司 使用包括脂质体伊立替康、奥沙利铂、5-氟尿嘧啶(和甲酰四氢叶酸)的组合疗法治疗胃癌
CN109939115B (zh) * 2019-05-06 2021-11-02 河南中医药大学 一种治疗放射性直肠炎的复方栓剂
US20230310478A1 (en) * 2020-09-02 2023-10-05 Ann And Robert H. Lurie Children's Hospital Of Chicago Methods and compositions for the treatment of pulmonary hypertension and cancer
CN114224875B (zh) * 2021-11-04 2023-08-11 中南大学湘雅医院 醇类化合物的新用途及抗肿瘤药物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998037892A1 (en) * 1997-02-27 1998-09-03 Pharmacia & Upjohn Company Tamoxifen as a therapy to reduce irinotecan hydrochloride-induced diarrhea
AU2592600A (en) * 1998-12-23 2000-07-31 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6395481B1 (en) * 1999-02-16 2002-05-28 Arch Development Corp. Methods for detection of promoter polymorphism in a UGT gene promoter
CA2295429A1 (en) * 2000-01-06 2001-07-06 Michael Michael Treatment or prevention of diarrhea
DE60120917T2 (de) * 2000-01-26 2007-01-25 Schering Corp. Kombinationspräparat zur krebstherapie
EP1286671B1 (en) * 2000-05-15 2006-04-05 Celgene Corporation Compositions for the treatment of colorectal cancer comprising thalidomide and irinotecan
WO2002028380A2 (en) * 2000-10-06 2002-04-11 Bristol-Myers Squibb Company Oral dosage forms for administration of the combination of tegafur, uracil, folinic acid, and irinotecan and method of using the same

Also Published As

Publication number Publication date
JP2005508312A (ja) 2005-03-31
WO2003013536A3 (en) 2003-12-18
EP1408975A2 (en) 2004-04-21
EP1408972A2 (en) 2004-04-21
WO2003013537A9 (en) 2004-04-29
WO2003013533A3 (en) 2003-10-09
AU2002328953A1 (en) 2003-02-24
CA2454637A1 (en) 2003-02-20
WO2003013535A2 (en) 2003-02-20
WO2003013534A9 (en) 2004-04-29
WO2003013535A9 (en) 2004-04-29
AU2002331290A1 (en) 2003-02-24
WO2003013537A3 (en) 2003-09-25
WO2003013537A2 (en) 2003-02-20
CA2454640A1 (en) 2003-02-20
US20050032724A1 (en) 2005-02-10
JP2005506971A (ja) 2005-03-10
AU2002328952A1 (en) 2003-02-24
EP1438050A2 (en) 2004-07-21
WO2003013534A3 (en) 2003-10-09
CA2454643A1 (en) 2003-02-20
AU2002328945A1 (en) 2003-02-24
WO2003013535A3 (en) 2003-09-25
WO2003013536A9 (en) 2004-04-29
JP2005501840A (ja) 2005-01-20
JP2005504759A (ja) 2005-02-17
EP1408974A2 (en) 2004-04-21
EP1408973A2 (en) 2004-04-21
WO2003013533A2 (en) 2003-02-20
WO2003013533A9 (en) 2004-04-29
JP2005505526A (ja) 2005-02-24
CA2454648A1 (en) 2003-02-20
AU2002328950A1 (en) 2003-02-24
WO2003013534A2 (en) 2003-02-20
WO2003013536A2 (en) 2003-02-20

Similar Documents

Publication Publication Date Title
CA2454627A1 (en) Methods for improved treatment of cancer with irinotecan based on mrp1
Mathijssen et al. Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan
Hanioka et al. Human liver UDP-glucuronosyltransferase isoforms involved in the glucuronidation of 7-ethyl-10-hydroxycamptothecin
Li et al. Apolipoprotein E-derived peptides ameliorate clinical disability and inflammatory infiltrates into the spinal cord in a murine model of multiple sclerosis
Kim et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans
Lu Drug-metabolism research challenges in the new millennium: individual variability in drug therapy and drug safety
US20020016293A1 (en) Flavopiridol drug combinations and methods with reduced side effects
Zhou et al. UGT1A1 gene polymorphisms and the toxicities of FOLFIRI in Chinese Han patients with gastrointestinal cancer
Stewart et al. Topoisomerase I interactive drugs in children with cancer
Dogruer et al. Lack of an effect of CYP3A4 and MDR1 gene polymorphisms on colchicine pharmacogenetics in the treatment of Familial Mediterranean fever
WO2003100091A1 (en) Means and methods for improved treatment using 'setrones'
Pangilinan et al. Irinotecan pharmacogenetics: an overview for the community oncologist
Fromm et al. The Pharmacogenomics of Human P‐Glycoprotein
Kim et al. Nilotinib-induced hyperbilirubinemia: Is it a negligible adverse event?
EP1789588A1 (en) Methods and its kits based on ugt1a7 promoter polymorphism
Lu et al. Pharmacogenetics, pharmacogenomics, and individualized medicine
Saito et al. 1A Haplotypes on Irinotecan
Vogelstein Genes Through the Species
Tsai et al. Significant correlation between polymorphisms of UGT1A1 gene and low irinotecan toxicity in colorectal cancer patients with FOLFIRI
EIS INHIBITOR GEFITINIB (“IRESSA") AND THE DNA TOPOISOMERASE I INHIBITOR CPT-11 (IRINOTECAN) IN HUMAN COLORECTAL CANCER CELLS
YANG PHARMACOKINETIC AND PHARMACODYNAMIC MECHANISMS FOR REDUCED TOXICITY OF CPT-11 BY THALIDOMIDE AND ST. JOHN’S WORT
Grem et al. Biochemical and molecular effects of UCN-01 in combination with 5-fluorodeoxyuridine in A431 human epidermoid cancer cells
Mcleod lrinotecan Disposition in Relation to Genetic Polymorphisms in ABC Transporters and Drug-Metabolizing Enzymes
Wang et al. Combination of dabrafenib with irinotecan might trigger off a higher frequency

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead